ulcer disease, renal disease (or impairment), or severe psoriasis or PsA, in which case apremilast may be given instead of NSAIDs. Tofacitinib is recommended over apremilast for treatment-naive patients with predominant enthesitis. Apremilast may be used instead of tofacitinib in patients with recurrent infections. In patients with active PsA with predominant enthesitis despite treatment with an OSM (used for other manifestations of PsA), a TNFi biologic, an IL-17i biologic, or an IL-12/23i